Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and best dose of a regimen
including bevacizumab and erlotinib in combination with docetaxel and prednisone. In
addition, the investigators wish to evaluate how well these drugs might work against this
disease. Bevacizumab and erlotinib are novel drugs that attack the blood vessels supplying
the tumor cells and attack a receptor on the tumor cells, respectively. This study has two
parts. In the first part of the study, eighteen patients will be enrolled. Patients will
receive escalating doses of docetaxel in combination with standard doses of bevacizumab and
erlotinib until the safest dose is determined. An additional 37 patients will enter into the
second part of the study and all will receive the safest dose. In this part of the study, the
effectiveness of this regimen against hormone refractory prostate cancer (HRPC) will be
monitored by evaluating prostate-specific antigen (PSA) and objective response of the tumor.